DEF 14A: Shuttle Pharmaceuticals Seeks Approval for Reverse Stock Split Amidst Phase 2 Trial Preparations

Shuttle Pharmaceuticals is asking shareholders to approve a reverse stock split while advancing its lead drug candidate, Ropidoxuridine, into a Phase 2 clinical trial for glioblastoma.

Summary

• Shuttle Pharmaceuticals is preparing to commence a Phase 2 clinical trial for Ropidoxuridine, a drug designed to enhance the effectiveness of radiation therapy in cancer treatment.
• The Phase 2 trial will initially involve 40 patients with aggressive brain tumors, randomized into two different doses (20 @ 1,200 mg/day and 20 @ 960 mg/day) to determine an optimal dose.
• An additional 14 patients will be added on the optimal dose allowing the company to achieve statistical significance with the end point being that of survival compared to historical controls.
• The company expects the trial to be completed over 18 to 24 months.
• Shuttle Pharmaceuticals is also seeking shareholder approval to authorize the Board of Directors to amend the company's certificate of incorporation to effect a reverse stock split of its common stock by a ratio in the range of 1-for-3 to 1-for-8.
• The company believes that the failure of stockholders to approve the Reverse Stock Split could prevent us from maintaining compliance with the Minimum Bid Price Requirement and could inhibit our ability to conduct capital raising activities, among other things.
• The Annual Meeting of Stockholders is scheduled for July 31, 2024, to vote on key proposals, including the election of directors, ratification of the independent auditor, executive compensation, and the reverse stock split authorization.

Sentiment

Score: 6

Explanation: The document presents a mix of positive developments (Phase 2 trial commencement) and concerning issues (reverse stock split for Nasdaq compliance). The sentiment is neutral, reflecting the inherent risks and uncertainties in the biotechnology industry.

Positives

• Ropidoxuridine is entering Phase 2 clinical trials, a significant milestone for the company.
• Shuttle Diagnostics aims to develop innovative diagnostic tests for prostate cancer, potentially improving treatment outcomes.
• The company has secured FDA approval to commence the Phase 2 clinical trial.
• The company has received central institutional review board (IRB) approval for the Phase 2 clinical trial and are in the process of finalizing site enrollment with up to six institutions.

Negatives

• The company is seeking a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, indicating potential financial challenges.
• The company's former independent registered public accounting firm, BF Borgers CPA PC (BF Borgers), was dismissed by the Company in March 2023 and on May 3, 2024, the SEC instituted administrative and cease-and-desist proceedings against BF Borgers which resulted in BF Borgers losing its ability to practice before the SEC.
• As a result, in an abundance of caution, we have chosen to re-audit our 2022 financial statements, with Forvis Mazars LLP performing the re-audit.
• While at present we do not believe there are any material errors in our 2022 financial statements, it is possible that there may be errors that will result in a restatement of our 2022 financial statements.

Risks

• The Phase 2 clinical trial may not yield positive results, impacting the future of Ropidoxuridine.
• The reverse stock split may not lead to a sustained increase in the stock price.
• Failure to maintain Nasdaq compliance could result in delisting and reduced liquidity.
• The company may face challenges in securing additional funding if the stock price remains low.

Future Outlook

The company anticipates completing the Phase 2 clinical trial over a period of 18 to 24 months and aims to develop Shuttle Diagnostics to offer prognosis and guide treatment decisions for prostate cancer patients.

Management Comments

• Anatoly Dritschilo, MD, Chairman and CEO: 'It is our belief that as we achieve important clinical development milestones in the years to come, it will create the desired value for our long-term shareholders.'

Industry Context

Shuttle Pharmaceuticals is operating in the competitive oncology therapeutics and diagnostics market, focusing on enhancing radiation therapy and developing predictive diagnostic tools. The company's success depends on positive clinical trial outcomes and successful commercialization of its products.

Comparison to Industry Standards

• Many pharmaceutical companies developing cancer therapies, such as Novocure (NVCR) with its Tumor Treating Fields (TTFields) therapy for glioblastoma, also face the challenges of clinical trials and regulatory approvals.
• Companies like Exact Sciences (EXAS) in the diagnostic space set a benchmark for developing and commercializing cancer diagnostic tests.
• Shuttle Pharmaceuticals' approach of combining radiation sensitizers with diagnostics aligns with the industry trend of personalized medicine.

Management Changes

Related Party Transactions

• In 2022 and 2023, Shuttle Pharmaceuticals contracted TCG GreenChem, where director Chris H. Senanayake is CEO and CSO, for process research, development, and cGMP compliant manufacture of IPdR, paying them $450,000 and $1,096,370 respectively.

Stakeholder Impact

• Shareholders will be impacted by the potential reverse stock split and the outcome of the Phase 2 clinical trial.
• Cancer patients, particularly those with glioblastoma, could benefit from successful development of Ropidoxuridine.
• Employees may be affected by the company's financial performance and strategic decisions.

Next Steps

• Commence Phase 2 clinical trial for Ropidoxuridine.
• Finalize site enrollment for the Phase 2 clinical trial.
• Shareholder vote on the reverse stock split proposal.
• Board of Directors decision on whether and when to implement the reverse stock split.
• Continued development of Shuttle Diagnostics.

Key Dates

Keywords

Ropidoxuridine, reverse stock split, glioblastoma, Phase 2 clinical trial, Shuttle Pharmaceuticals, radiation sensitizers, prostate cancer, Shuttle Diagnostics, FDA, Annual Meeting